Newly Released Agenda for Biosimilars Europe 2016 to Feature Talks from Merck, Boehringer Ingelheim and Bristows LLC

Share Article

SMi Group is thrilled to present the 7th annual conference, Biosimilars Europe, taking place on 29th & 30th September 2016 in Central London, UK.

Biosimilars Europe 2016

Biosimilars Europe 2016

Past Attendee Testimonials: "Really wide range of topics" - Kantar Health; "Rich in information and quality speakers" - Globyz Pharma; "Great discussions, networking and education" - Apobiologix

SMi are delighted to announce that registration is now live to attend Biosimilars Europe, set to take place this autumn in London, UK.

Widely recognized as one of the most profitable areas of drug development, the global biosimilars market is expected to grow at a CAGR of 40.3% by 2020.*Source:

With a raising demand for cost effective biosimilar drugs, Biosimilars Europe 2016 returns for its 7th annual show to showcase the latest updates in regulation, patent expiries and tactical approaches to market entry through informed guidance delivered by a panel of speakers that includes Merck Group, Boehringer Ingelheim GmbH, Bristows LLC and various medical agencies from across Europe.


  • Insight into future projections presented in an opening keynote by industry specialist, Dr Duncan Emerton, FirstWord.
  • 1st hand experience on strategy and portfolio management in a VUCA (Volatile, Uncertain, Complex & Ambiguous) world through a case study on emerging biosimilars, presented by Merck Group.
  • Case study updates into both USA and UK litigation with Bristows LLP.
  • Guidance into entering emerging markets with insight into current guidelines, regulation, and pricing & reimbursement strategies, from Shanghai CP Guojian Pharmaceuticals.
  • A spotlight session on commercialisation featuring talks from RJW & Partners and Abzena.
  • A spotlight session on cutting edge technological developments with progressive outlook into bioanalytical analysis, yielding 3D structure of monoclonal antibodies, and opportunities for biosimilars in medical device components.


  • Huiguo Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co Ltd
  • Dr Niraj Chhaya, Risk Management, Boehringer Ingelheim GmbH
  • Atanas Dimitrov, Head of Strategy & Portfolio Management, Merck Group
  • Dr Alok Sharma, Head, Bio-Analytical Development, Lupin Ltd
  • Dr Andrea Laslop, Head of Scientific Office, Austrian Agency for Health and Food Safety
  • Joan O’Callaghan, Research Scientist for Regulatory Science Ireland, Health Products Regulatory Authority, Ireland

The full line-up and detailed agenda is available online at
Biosimilars Europe 2016
Conference: 29th & 30th Sept 2016 | Interactive Workshops: 28th Sept 2016
Holiday Inn Kensington Forum, London UK

Sponsored by: Abzena

--- end ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Teri Arri
SMi Group
+44 2078276162
Email >
since: 10/2011
Follow >
Visit website